Immunic, Inc. (IMUX)
$8.19+8.33%Close
SELLCRISIS · day 28
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $112M
- Beta
- 1.45
- P/E (TTM)
- -1.63
- Short % float
- 17.53%
- Days to cover
- 4.6
- SI change
- +15.7%
- 1W
- +2.89%
- 1M
- -30.83%
- vs SPY 1W
- +1.73%
- vs SPY 1M
- -33.82%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IMUX?
- LOPJLB’s latest quantitative signal on Immunic, Inc. (IMUX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMUX in?
- Immunic, Inc. (IMUX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immunic, Inc. (IMUX) do?
- Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other…